LUMACAFTOR AND IVACAFTOR and INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS

Overview

INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS is the #1 most commonly reported adverse reaction for LUMACAFTOR AND IVACAFTOR, manufactured by Vertex Pharmaceuticals Incorporated. There are 1,460 FDA adverse event reports linking LUMACAFTOR AND IVACAFTOR to INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS. This represents approximately 12.1% of all 12,020 adverse event reports for this drug.

Patients taking LUMACAFTOR AND IVACAFTOR who experience infective pulmonary exacerbation of cystic fibrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS is a frequently reported adverse event for LUMACAFTOR AND IVACAFTOR, accounting for a significant proportion of all reports.

Other Side Effects of LUMACAFTOR AND IVACAFTOR

In addition to infective pulmonary exacerbation of cystic fibrosis, the following adverse reactions have been reported for LUMACAFTOR AND IVACAFTOR:

• HOSPITALISATION — 885 reports
• DYSPNOEA — 555 reports
• PULMONARY FUNCTION TEST DECREASED — 396 reports
• COUGH — 391 reports
• INFECTION — 369 reports
• CHEST DISCOMFORT — 343 reports
• CYSTIC FIBROSIS — 325 reports
• PNEUMONIA — 268 reports
• MALAISE — 224 reports
• NASOPHARYNGITIS — 202 reports

Other Drugs Associated with INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS

The following drugs have also been linked to infective pulmonary exacerbation of cystic fibrosis in FDA adverse event reports:

Does LUMACAFTOR AND IVACAFTOR cause INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS?

INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS has been reported as an adverse event in 1,460 FDA reports for LUMACAFTOR AND IVACAFTOR. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS with LUMACAFTOR AND IVACAFTOR?

INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS accounts for approximately 12.1% of all adverse event reports for LUMACAFTOR AND IVACAFTOR, making it one of the most commonly reported side effect.

What should I do if I experience INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS while taking LUMACAFTOR AND IVACAFTOR?

If you experience infective pulmonary exacerbation of cystic fibrosis while taking LUMACAFTOR AND IVACAFTOR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages